Follows people with neurofibromatosis 1 treated with selumetinib in routine care
Observes safety and results of selumetinib in people with plexiform neurofibromas.
Plain-language title generated from the registry record
Registry title: Real-World Treatment Study of Koselugo (Selumetinib)
Key facts
- Where
- Busan, Chungcheongbuk-do, Daejeon, Gyeonggi-do, Incheon, Jeonnam, Seoul, Wŏnju, and Yangsan, South KoreaSee the 9 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 3 and 99 years old?
Source: NCT06360406, who can take part
Where in South Korea
- BusanBusan, South KoreaTaking people
- Chungcheongbuk-doChungcheongbuk-do, South KoreaTaking people
- DaejeonDaejeon, South KoreaTaking people
- Gyeonggi-doGyeonggi-do, South KoreaTaking people
- IncheonIncheon, South KoreaTaking people
- JeonnamJeonnam, South KoreaTaking people
- SeoulSeoul, South KoreaNo longer taking part
- WŏnjuWŏnju, South KoreaTaking people
- YangsanYangsan, South KoreaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- AstraZeneca
- Trial code
- NCT06360406
- Record updated
- 25 August 2026
- Original description
As part of a post-approval commitment, the Korean health authority requests a study to characterize safety and effectiveness in patients treated with Koselugo (Selumetinib), an oral selective inhibitor of MAPK kinase (MEK) 1 and 2, by physicians in routine clinical practice settings. This study is designed to assess the known safety profile or identify previously unsuspected adverse reactions and evaluate the effectiveness of Koselugo under conditions of routine daily medical practice in Korea.Read full original descriptionShow less
Real-World Treatment Study of Koselugo (Selumetinib)
As part of a post-approval commitment, the Korean health authority requests a study to characterize safety and effectiveness in patients treated with Koselugo (Selumetinib), an oral selective inhibitor of MAPK kinase (MEK) 1 and 2, by physicians in routine clinical practice settings. This study is designed to assess the known safety profile or identify previously unsuspected adverse reactions and evaluate the effectiveness of Koselugo under conditions of routine daily medical practice in Korea.
This study will provide information on the Korean patient population that is treated with the study drug.
Inclusion: Patients treated with Koselugo (Selumetinib) under the approved label in South Korea; Provision of signed and dated written informed consent by the patient or legally acceptable representative.
Exclusion: Patients treated with Koselugo (Selumetinib) under the approved label in South Korea; Provision of signed and dated written informed consent by the patient or legally acceptable representative.